Protara Therapeutics Inc. Common Stock (TARA)
Stock · NASDAQ · Health Care
$2.34as of 10/16/2026
Price chart
Active signals
TARA Signal Track Record
How signals performed across all stocks →What TARA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 49 | +0.9% | 51% | September 18, 2026 |
| Bollinger Band Breakdown | 21 | -2.0% | 43% | September 30, 2026 |
| Bollinger Band Breakout | 23 | -5.9% | 43% | May 6, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -5.7% | 27% | May 15, 2026 |
| Any 20-session window (baseline) | -3.1% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an invest…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 46
- Website
- protaratx.com/
Fundamentals
- 1-day range
- $2.32$2.47
- Market cap
- $230.44M
- P/E (trailing)
- —
- P/E (forward)
- -1.37
- EPS (trailing)
- $-1.35
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 847.2K
- Dividend pay date
- January 10, 2020
How Protara Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2014 annual results
Source: 10-K filed Mar 20, 2015 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Protara Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TARAProtara Therapeutics Inc. Common Stock$2.32▼ 3.33%Market cap $230.44MP/E —$2.38$7.82
- CGENCompugen Ltd. Ordinary Shares$1.96▼ 5.77%Market cap $217.54MP/E 5.59$1.43$3.24
- SRZNSurrozen Inc. Common Stock$23.44▼ 6.50%Market cap $251.25MP/E —$11.39$37.83
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TARA Protara Therapeutics Inc. Common Stock | $230.44M | — | $2.32 | ▼ 3.33% | $2.38$7.82 |
| CGEN Compugen Ltd. Ordinary Shares | $217.54M | 5.59 | $1.96 | ▼ 5.77% | $1.43$3.24 |
| SRZN Surrozen Inc. Common Stock | $251.25M | — | $23.44 | ▼ 6.50% | $11.39$37.83 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Jesse Shefferman · June 30, 2026 · Gift5.0K
- Jesse Shefferman · June 30, 2026 · Gift4.0K
- Jesse Shefferman · June 30, 2026 · Gift7.0K
- Jesse Shefferman · June 30, 2026 · Gift14.0K
- Jesse Shefferman · June 29, 2026 · Option Exercise215.7K @ $1.91
- Jesse Shefferman · June 29, 2026 · Sale215.7K @ $4.09
- Richard S. Levy · June 15, 2026 · Grant31.0K
- Jane Huang · June 15, 2026 · Grant31.0K
- GARCEAU ROGER · June 15, 2026 · Grant31.0K
- Flannelly Barry P · June 15, 2026 · Grant31.0K
- SARGEN GREGORY · June 15, 2026 · Grant31.0K
- BESHAR LUKE M · June 15, 2026 · Grant31.0K
- Solomon Michael Edward · June 15, 2026 · Grant31.0K
- Smith Cynthia · June 15, 2026 · Grant31.0K
- William Conkling · June 2, 2026 · Tax Withholding6.0K @ $4.34
Institutional Ownership
March 31, 2026
- Total shares held
- 44.87M
- Total value held
- $233.54M
- Institutional holders
- 109
- Unknown5.21M
- Unknown3.39M
- Unknown2.83M
- Unknown2.83M
- Unknown2.27M
- Unknown2.12M
- Unknown1.97M
- Unknown1.75M
- Unknown1.75M
- Unknown1.62M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.